{"title":"Covid-19疫苗的研究与开发","authors":"N. Ekong","doi":"10.35248/2157-7560.21.S10.E001","DOIUrl":null,"url":null,"abstract":"The first generation covid-19 vaccine was expected to come by the end of 2020 or beginning of 2021. The vaccine was developed to provide immunity to the population and to reduce the spread of the infection or the virus. There are more than 5 vaccines which are developed and under the phase 3 clinical trials to test the safety, efficacy, quality and purity of vaccine. The WHO recommends that the vaccine need to show at least 50% risk reduction for causing infection and 95% efficacy in treating and curing the infected patient and100% safety rate to be approved [3].","PeriodicalId":17656,"journal":{"name":"Journal of Vaccines and Vaccination","volume":"112 1","pages":"1-1"},"PeriodicalIF":0.0000,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":"{\"title\":\"Research and Development of Covid-19 Vaccine\",\"authors\":\"N. Ekong\",\"doi\":\"10.35248/2157-7560.21.S10.E001\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"The first generation covid-19 vaccine was expected to come by the end of 2020 or beginning of 2021. The vaccine was developed to provide immunity to the population and to reduce the spread of the infection or the virus. There are more than 5 vaccines which are developed and under the phase 3 clinical trials to test the safety, efficacy, quality and purity of vaccine. The WHO recommends that the vaccine need to show at least 50% risk reduction for causing infection and 95% efficacy in treating and curing the infected patient and100% safety rate to be approved [3].\",\"PeriodicalId\":17656,\"journal\":{\"name\":\"Journal of Vaccines and Vaccination\",\"volume\":\"112 1\",\"pages\":\"1-1\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2021-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"1\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Vaccines and Vaccination\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.35248/2157-7560.21.S10.E001\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Vaccines and Vaccination","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.35248/2157-7560.21.S10.E001","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
The first generation covid-19 vaccine was expected to come by the end of 2020 or beginning of 2021. The vaccine was developed to provide immunity to the population and to reduce the spread of the infection or the virus. There are more than 5 vaccines which are developed and under the phase 3 clinical trials to test the safety, efficacy, quality and purity of vaccine. The WHO recommends that the vaccine need to show at least 50% risk reduction for causing infection and 95% efficacy in treating and curing the infected patient and100% safety rate to be approved [3].